Keating Financial Advisory Services’s Soleno Therapeutics SLNO Stock Holding History

Keating Financial Advisory Services’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-4	Closed	-$134	–	2700
2026 Q1	$134	Sell	4 -50	-93%	-$1.96K	﹤0.01%	2393
2025 Q4	$2.5K	Buy	+54	New	+$2.96K	﹤0.01%	1512

Keating Financial Advisory Services's SLNO Position: Q2 2026 in Review

Keating Financial Advisory Services sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 4 shares — an estimated $134 sold.

Keating Financial Advisory Services first reported a position in SLNO in Q4 2025 and held it in 2 quarters. The position peaked at $2.5K in Q4 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Keating Financial Advisory Services reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Keating Financial Advisory Services sold 4 Soleno Therapeutics shares in Q2 2026, an estimated $134.
Keating Financial Advisory Services first reported a position in Soleno Therapeutics in Q4 2025 and held it in 2 quarters.
Keating Financial Advisory Services's Soleno Therapeutics position peaked at $2.5K in Q4 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.